Accordingly, payers and clinicians will need to implement risk-stratified algorithms, based on non-invasive fibrosis scores, metabolic comorbidities, and patient preferences, to decide who should be treated now, who can safely defer pharmacotherapy, and how limited resources can be deployed most equitably
Manufacturers often explore delivery methods like liposomes or nanoparticles to enhance oral bioavailability
Among these, ctDNA shows potential as an early diagnostic tool for HCC and can be found in a various early stage tumers such as colorectal cancer, ovarian cancer, lung cancer and breast cancer (Phallen et al., 2017)
The peptide is stable in gastric acid, which makes oral administration viable for gut-targeted applications, a property that distinguishes it from many other therapeutic peptides that degrade before reaching target tissue